logo

Uniqure N.V. (QURE)



Trade QURE now with
  Date
  Headline
7/27/2021 10:00:33 AM UniQure Shares Rise On Upbeat Q2
10/13/2020 7:13:24 AM UniQure Says Two Additional Patient Procedures Completed In Phase I/II Clinical Trial Of AMT-130
9/25/2020 7:09:15 AM UniQure Announces Recommendations From DSMB Of Phase I/II Clinical Trial Of AMT-130 For Huntington’s Disease
8/26/2020 7:36:37 AM UniQure Appoints Ricardo Dolmetsch As President, Research & Development
6/25/2020 11:18:43 AM Stock Alert: UniQure Down 20%
6/24/2020 6:33:51 PM CSL Behring Agrees To Buy Novel Late-Stage Gene Therapy Candidate For Hemophilia B Patients From UniQure
6/19/2020 7:22:28 AM UniQure Announces First Two Patients Treated In Phase I/II Clinical Trial Of AMT-130 For Huntington’s Disease
6/17/2020 4:16:22 PM UniQure Appoints Leonard Post To Its Board Of Directors
4/17/2020 7:06:05 AM UniQure Announces Nomination Of Leonard Post To Its Board
11/22/2016 1:38:10 PM Jefferies Is Lowering uniQure N.V. (QURE) 2018 Estimate To -1.96 From -1.83
11/22/2016 1:37:47 PM Jefferies Is Cutting uniQure N.V. (QURE) 2017 Estimate To -2.23 From -2.15
11/22/2016 1:37:27 PM Jefferies Is Raising uniQure N.V. (QURE) 2016 Estimate To -2.83 From -3.40
11/22/2016 1:37:07 PM Jefferies Is Increasing uniQure N.V. (QURE) Q4 16 Estimate To -0.72 From -0.93
11/21/2016 5:53:15 PM Jefferies Downgrades uniQure N.V. (QURE) To Hold From Buy With $8 Down From $28 Price Target
4/4/2016 12:15:03 PM Jefferies Is Cutting uniQure N.V. (QURE) 2017 Estimate To -2.72 From -2.27